サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1463813

瘢痕治療の世界市場：市場規模・シェア分析 (治療の種類別・瘢痕の種類別・エンドユーザー別)、産業の需要予測 (～2030年)

Scar Treatment Market Size and Share Analysis by Treatment Type, Scar Type, End User - Global Industry Demand Forecast to 2030
出版日: | 発行: Prescient & Strategic Intelligence | ページ情報: 英文 310 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
瘢痕治療の世界市場：市場規模・シェア分析 (治療の種類別・瘢痕の種類別・エンドユーザー別)、産業の需要予測 (～2030年)
出版日: 2024年04月01日
発行: Prescient & Strategic Intelligence
ページ情報: 英文 310 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

主なハイライト

世界の瘢痕治療市場は、2023年に238億米ドル、2030年には528億米ドルの規模に達し、12.0%以上のCAGRで成長します。

傷跡管理に関する意識の高まり、完璧な肌を手に入れたいという人々の関心の高まり、美容整形に対するニーズの急増、医療技術の進化が業界の拡大を後押ししています。

レーザー、ケミカルピーリング、マイクロダーマブレージョン、ダーマブレージョンなど、現在利用可能な改良された美容手段があります。このような進歩により、美的感覚を向上させるためにより効果的な選択肢を提供することが可能になりました。

市場の洞察

北米は2023年に約37.8%のシェアを占め、最大の地域となりました。

北米では可処分所得が高く、その結果パーソナルケア製品にかかる費用が増加していることが、この地域の業界を支配している主な要因です。

2023年、米国は北米産業への最大の貢献国であり、この10年間はより速いCAGRで進歩する可能性が高いです。

レーザーのカテゴリーは、この10年間で12.7%と最も高い成長率を示すと思われます。これは、レーザー治療が現在利用可能な治療法よりも進んでいるためです。

萎縮性瘢痕およびにきび瘢痕は、2023年には40.1%のシェアで業界最大を占め、この10年間を通じて最大であり続けると思われます。

ケロイドと肥厚性瘢痕のカテゴリーは、今後数年間で最も速いCAGRで成長すると思われます。これは、火傷や外傷の発生率と相まって手術件数が増加しているためです。

当レポートでは、世界の瘢痕治療の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、治療の種類別・瘢痕の種類別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

  • 市場力学
    • 動向
    • 促進要因
    • 抑制要因/課題
    • 促進要因/抑制要因の影響分析
  • 新型コロナウイルス感染症 (COVID-19) の影響
  • ポーターのファイブフォース分析

第6章 世界市場

  • 概要
  • 市場収益：治療の種類別 (2017～2030年)
    • 局所治療の市場収益：種類別 (2017年～2030年)
    • 表面治療の市場収益：種類別 (2017年～2030年)
    • レーザー治療の市場収益：種類別 (2017年～2030年)
    • 注射治療の市場収益：種類別 (2017年～2030年)
  • 市場収益：瘢痕の種類別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)
  • 市場収益：地域別 (2017～2030年)

第7章 北米市場

  • 概要
  • 市場収益：治療の種類別 (2017～2030年)
    • 局所治療の市場収益：種類別 (2017年～2030年)
    • 表面治療の市場収益：種類別 (2017年～2030年)
    • レーザー治療の市場収益：種類別 (2017年～2030年)
    • 注射治療の市場収益：種類別 (2017年～2030年)
  • 市場収益：瘢痕の種類別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)
  • 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

  • 概要
  • 市場収益：治療の種類別 (2017～2030年)
    • 局所治療の市場収益：種類別 (2017年～2030年)
    • 表面治療の市場収益：種類別 (2017年～2030年)
    • レーザー治療の市場収益：種類別 (2017年～2030年)
    • 注射治療の市場収益：種類別 (2017年～2030年)
  • 市場収益：瘢痕の種類別 (2017～2030年)
  • 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

  • 市場参入企業とその提供品目の一覧
  • 主要企業の競合ベンチマーク
  • 主要企業の製品ベンチマーク
  • 最近の戦略展開状況

第30章 企業プロファイル

  • Avita Medical Inc.
  • Revitol Corporation
  • Sonoma Pharmaceuticals Inc.
  • Molnlycke Health Care AB
  • CCA Industries Inc.
  • Sisram Medical Ltd.
  • Biodermis
  • Candela Corporation
  • Smith & Nephew plc
  • Scarguard Labs LLC

第31章 付録

目次
Product Code: 10180

Key Highlights

The scar treatment market generated a value of USD 23.8 billion in 2023, which will rise to USD 52.8 billion, advancing at over 12.0% CAGR, by 2030.

The rising consciousness regarding scar management, increasing interest of people in having flawless skin, surging need for cosmetic procedures, and evolving medical technology are aiding the industry expansion.

Individuals with long-term disfigurement due to burns, accidents, surgery, or other reasons are searching for effective means to improve their appearance.

The development of different therapies that decrease the scar's visibility and improve the overall skin texture has been enabled by the improvements in medical technology.

The improved cosmetic measures now accessible comprise lasers, chemical peels, microdermabrasion, and dermabrasion.

These advancements have made it possible to offer less intrusive as well as more effective choices to individuals for improving their aesthetics.

There has been an increasing acceptance of scar revision solutions because of the rising consciousness about the different options of treatment accessible.

The public has profited from the information provided by plastic surgeons, skincare experts, and dermatologists about the benefits of under-trial and current skin treatments.

With the arrival of elective surgeries and medical tourism, the count of surgical measures is increasing at a significant pace. This means that now, more potential patients are searching for post-surgery scar treatment.

Market Insights

North America was the largest contributor to the industry in 2023, with a share of approximately 37.8%.

The high disposable salary in North America, which results in a rise in the expenses on personal care products, is a major contributor to the dominance of the regional industry.

In 2023, the U.S. was the largest contributor to the industry in North America, and it is likely to advance at a faster compound annual growth rate during this decade.

The laser category will advance at the highest rate, of 12.7%, during this decade. This will be because laser treatments are more advanced than the currently accessible topical therapies.

Atrophic and acne scars accounted for the largest share of the industry in 2023, with a 40.1% share, and it will remain the largest throughout this decade.

Acne is among of the most common dermatological conditions globally, particularly among adolescents.

Acne occurs because of the clogging of the hair follicles in the skin with sebum, dirt, oil, dead skin cells, and various other impurities, which leads to lesions formation.

Approximately 9.4% of the global population suffers from acne, making it the 8th most prevalent illness in the world.

The keloid and hypertrophic scar category will propel at the fastest CAGR in the years to come. This will be because of the rising volume of surgeries, coupled with the incidence of burn injuries as well as traumatic wounds.

The scar treatment industry is moderately fragmented with the existence of some local players. Players in this industry are trying to enhance their presence by implementing strategies like mergers & acquisitions, partnerships, and investments.

The industry players are also concentrating on sustaining competitive pricing and investing in developing greater and more effective products.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by treatment type
    • 1.4.2. Market size breakdown, by scar type
    • 1.4.3. Market size breakdown, by end user
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Treatment Type (2017-2030)
    • 6.2.1. Topical market revenue, by type (2017-2030)
    • 6.2.2. Surface market revenue, by type (2017-2030)
    • 6.2.3. Laser market revenue, by type (2017-2030)
    • 6.2.4. Injectable market revenue, by type (2017-2030)
  • 6.3. Market Revenue, by Scar Type (2017-2030)
  • 6.4. Market Revenue, by End User (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Treatment Type (2017-2030)
    • 7.2.1. Topical market revenue, by type (2017-2030)
    • 7.2.2. Surface market revenue, by type (2017-2030)
    • 7.2.3. Laser market revenue, by type (2017-2030)
    • 7.2.4. Injectable market revenue, by type (2017-2030)
  • 7.3. Market Revenue, by Scar Type (2017-2030)
  • 7.4. Market Revenue, by End User (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Treatment Type (2017-2030)
    • 8.2.1. Topical market revenue, by type (2017-2030)
    • 8.2.2. Surface market revenue, by type (2017-2030)
    • 8.2.3. Laser market revenue, by type (2017-2030)
    • 8.2.4. Injectable market revenue, by type (2017-2030)
  • 8.3. Market Revenue, by Scar Type (2017-2030)
  • 8.4. Market Revenue, by End User (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Treatment Type (2017-2030)
    • 9.2.1. Topical market revenue, by type (2017-2030)
    • 9.2.2. Surface market revenue, by type (2017-2030)
    • 9.2.3. Laser market revenue, by type (2017-2030)
    • 9.2.4. Injectable market revenue, by type (2017-2030)
  • 9.3. Market Revenue, by Scar Type (2017-2030)
  • 9.4. Market Revenue, by End User (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Treatment Type (2017-2030)
    • 10.2.1. Topical market revenue, by type (2017-2030)
    • 10.2.2. Surface market revenue, by type (2017-2030)
    • 10.2.3. Laser market revenue, by type (2017-2030)
    • 10.2.4. Injectable market revenue, by type (2017-2030)
  • 10.3. Market Revenue, by Scar Type (2017-2030)
  • 10.4. Market Revenue, by End User (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Treatment Type (2017-2030)
    • 11.2.1. Topical market revenue, by type (2017-2030)
    • 11.2.2. Surface market revenue, by type (2017-2030)
    • 11.2.3. Laser market revenue, by type (2017-2030)
    • 11.2.4. Injectable market revenue, by type (2017-2030)
  • 11.3. Market Revenue, by Scar Type (2017-2030)
  • 11.4. Market Revenue, by End User (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Treatment Type (2017-2030)
    • 12.2.1. Topical market revenue, by type (2017-2030)
    • 12.2.2. Surface market revenue, by type (2017-2030)
    • 12.2.3. Laser market revenue, by type (2017-2030)
    • 12.2.4. Injectable market revenue, by type (2017-2030)
  • 12.3. Market Revenue, by Scar Type (2017-2030)
  • 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Treatment Type (2017-2030)
    • 13.2.1. Topical market revenue, by type (2017-2030)
    • 13.2.2. Surface market revenue, by type (2017-2030)
    • 13.2.3. Laser market revenue, by type (2017-2030)
    • 13.2.4. Injectable market revenue, by type (2017-2030)
  • 13.3. Market Revenue, by Scar Type (2017-2030)
  • 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Treatment Type (2017-2030)
    • 14.2.1. Topical market revenue, by type (2017-2030)
    • 14.2.2. Surface market revenue, by type (2017-2030)
    • 14.2.3. Laser market revenue, by type (2017-2030)
    • 14.2.4. Injectable market revenue, by type (2017-2030)
  • 14.3. Market Revenue, by Scar Type (2017-2030)
  • 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Treatment Type (2017-2030)
    • 15.2.1. Topical market revenue, by type (2017-2030)
    • 15.2.2. Surface market revenue, by type (2017-2030)
    • 15.2.3. Laser market revenue, by type (2017-2030)
    • 15.2.4. Injectable market revenue, by type (2017-2030)
  • 15.3. Market Revenue, by Scar Type (2017-2030)
  • 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Treatment Type (2017-2030)
    • 16.2.1. Topical market revenue, by type (2017-2030)
    • 16.2.2. Surface market revenue, by type (2017-2030)
    • 16.2.3. Laser market revenue, by type (2017-2030)
    • 16.2.4. Injectable market revenue, by type (2017-2030)
  • 16.3. Market Revenue, by Scar Type (2017-2030)
  • 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Treatment Type (2017-2030)
    • 17.2.1. Topical market revenue, by type (2017-2030)
    • 17.2.2. Surface market revenue, by type (2017-2030)
    • 17.2.3. Laser market revenue, by type (2017-2030)
    • 17.2.4. Injectable market revenue, by type (2017-2030)
  • 17.3. Market Revenue, by Scar Type (2017-2030)
  • 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Treatment Type (2017-2030)
    • 18.2.1. Topical market revenue, by type (2017-2030)
    • 18.2.2. Surface market revenue, by type (2017-2030)
    • 18.2.3. Laser market revenue, by type (2017-2030)
    • 18.2.4. Injectable market revenue, by type (2017-2030)
  • 18.3. Market Revenue, by Scar Type (2017-2030)
  • 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Treatment Type (2017-2030)
    • 19.2.1. Topical market revenue, by type (2017-2030)
    • 19.2.2. Surface market revenue, by type (2017-2030)
    • 19.2.3. Laser market revenue, by type (2017-2030)
    • 19.2.4. Injectable market revenue, by type (2017-2030)
  • 19.3. Market Revenue, by Scar Type (2017-2030)
  • 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Treatment Type (2017-2030)
    • 20.2.1. Topical market revenue, by type (2017-2030)
    • 20.2.2. Surface market revenue, by type (2017-2030)
    • 20.2.3. Laser market revenue, by type (2017-2030)
    • 20.2.4. Injectable market revenue, by type (2017-2030)
  • 20.3. Market Revenue, by Scar Type (2017-2030)
  • 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Treatment Type (2017-2030)
    • 21.2.1. Topical market revenue, by type (2017-2030)
    • 21.2.2. Surface market revenue, by type (2017-2030)
    • 21.2.3. Laser market revenue, by type (2017-2030)
    • 21.2.4. Injectable market revenue, by type (2017-2030)
  • 21.3. Market Revenue, by Scar Type (2017-2030)
  • 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Treatment Type (2017-2030)
    • 22.2.1. Topical market revenue, by type (2017-2030)
    • 22.2.2. Surface market revenue, by type (2017-2030)
    • 22.2.3. Laser market revenue, by type (2017-2030)
    • 22.2.4. Injectable market revenue, by type (2017-2030)
  • 22.3. Market Revenue, by Scar Type (2017-2030)
  • 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Treatment Type (2017-2030)
    • 23.2.1. Topical market revenue, by type (2017-2030)
    • 23.2.2. Surface market revenue, by type (2017-2030)
    • 23.2.3. Laser market revenue, by type (2017-2030)
    • 23.2.4. Injectable market revenue, by type (2017-2030)
  • 23.3. Market Revenue, by Scar Type (2017-2030)
  • 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Treatment Type (2017-2030)
    • 24.2.1. Topical market revenue, by type (2017-2030)
    • 24.2.2. Surface market revenue, by type (2017-2030)
    • 24.2.3. Laser market revenue, by type (2017-2030)
    • 24.2.4. Injectable market revenue, by type (2017-2030)
  • 24.3. Market Revenue, by Scar Type (2017-2030)
  • 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Treatment Type (2017-2030)
    • 25.2.1. Topical market revenue, by type (2017-2030)
    • 25.2.2. Surface market revenue, by type (2017-2030)
    • 25.2.3. Laser market revenue, by type (2017-2030)
    • 25.2.4. Injectable market revenue, by type (2017-2030)
  • 25.3. Market Revenue, by Scar Type (2017-2030)
  • 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Treatment Type (2017-2030)
    • 26.2.1. Topical market revenue, by type (2017-2030)
    • 26.2.2. Surface market revenue, by type (2017-2030)
    • 26.2.3. Laser market revenue, by type (2017-2030)
    • 26.2.4. Injectable market revenue, by type (2017-2030)
  • 26.3. Market Revenue, by Scar Type (2017-2030)
  • 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Treatment Type (2017-2030)
    • 27.2.1. Topical market revenue, by type (2017-2030)
    • 27.2.2. Surface market revenue, by type (2017-2030)
    • 27.2.3. Laser market revenue, by type (2017-2030)
    • 27.2.4. Injectable market revenue, by type (2017-2030)
  • 27.3. Market Revenue, by Scar Type (2017-2030)
  • 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Treatment Type (2017-2030)
    • 28.2.1. Topical market revenue, by type (2017-2030)
    • 28.2.2. Surface market revenue, by type (2017-2030)
    • 28.2.3. Laser market revenue, by type (2017-2030)
    • 28.2.4. Injectable market revenue, by type (2017-2030)
  • 28.3. Market Revenue, by Scar Type (2017-2030)
  • 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Avita Medical Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Revitol Corporation
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Sonoma Pharmaceuticals Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Molnlycke Health Care AB
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. CCA Industries Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Sisram Medical Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Biodermis
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Candela Corporation
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Smith & Nephew plc
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Scarguard Labs LLC
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports